Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Fig. 3

A The survival difference in progression-free survival (PFS) between immune checkpoint inhibitors (ICIs) combined with chemotherapy and ICIs combined with anti-angiogenic therapy. B The survival difference in overall survival (OS) between ICIs combined with chemotherapy and ICIs combined with anti-angiogenic therapy. C The survival difference in PFS between ICIs combined with chemotherapy and ICIs combined with chemotherapy and anti-angiogenic therapy. D The survival difference in OS between ICIs combined with chemotherapy and ICIs combined with chemotherapy and anti-angiogenic therapy. E The survival difference in PFS between ICIs combined with anti-angiogenic therapy and ICIs combined with chemotherapy and anti-angiogenic therapy. F The survival difference in OS between ICIs combined with anti-angiogenic therapy and ICIs combined with chemotherapy and anti-angiogenic therapy

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us